Ecuador studies production of Sputnik V vaccine in its territory

The drug, developed by Moscow's Nikolai Gamaleya Center for Epidemiology and Microbiology with funding from the Russian Direct Investment Fund, was registered in Russia in August 2020 and is one of the few globally with greater than 90% efficacy against COVID-19.

RIO DE JANEIRO, BRAZIL - Quito continues to analyze the possibility of production of the Russian vaccine Sputnik . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?